Literature DB >> 1919609

The thymus in seronegative myasthenia gravis patients.

N Willcox1, M Schluep, M A Ritter, J Newsom-Davis.   

Abstract

In 5-10% of all patients with typical generalised myasthenia gravis (MG), serum antibody to the acetylcholine receptor (AChR) is undetectable. To determine whether these represent a distinct subgroup, we have compared the thymuses of 14 seronegatives, 70 seropositives and 12 non-myasthenic controls. By quantitative immunohistology on coded sections, the 7 seronegative samples were clearly distinguishable from the controls by the pronounced lymph node-type T-cell areas in the medulla. While these closely resembled those in the seropositive cases, germinal centres were significantly sparser, and total in vitro IgG production was disproportionately low (per B cell) in the 12 cases tested. Furthermore, specific anti-AChR production was never detected in any of these cultures. The data support the view that the medullary T-cell areas are the most consistent abnormality in the MG thymus (though it may not be primary), and they strongly imply that seronegative and seropositive MG are distinct entities.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1919609     DOI: 10.1007/bf00319736

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  21 in total

1.  Intrathymic pathogenesis and dual genetic control of myasthenia gravis.

Authors:  H Wekerle; U P Ketelsen
Journal:  Lancet       Date:  1977-03-26       Impact factor: 79.321

2.  Greatly increased autoantibody production in myasthenia gravis by thymocyte suspensions prepared with proteolytic enzymes.

Authors:  H N Willcox; J Newsom-Davis; L R Calder
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

3.  Acetylcholine receptor antibody synthesis by thymic lymphocytes: correlation with thymic histology.

Authors:  G K Scadding; A Vincent; J Newsom-Davis; K Henry
Journal:  Neurology       Date:  1981-08       Impact factor: 9.910

Review 4.  Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients.

Authors:  K E Osserman; G Genkins
Journal:  Mt Sinai J Med       Date:  1971 Nov-Dec

5.  Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells.

Authors:  N Sommer; N Willcox; G C Harcourt; J Newsom-Davis
Journal:  Ann Neurol       Date:  1990-09       Impact factor: 10.422

6.  Patterns of acetylcholine receptor antibody fluctuation in myasthenia gravis.

Authors:  M E Seybold; J M Lindstrom
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

7.  Acetylcholine receptor antibody characteristics in myasthenia gravis. III. Patients with low anti-AChR antibody levels.

Authors:  A Vincent; J Newsom-Davis
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

8.  Thymectomy in myasthenia with pure ocular symptoms.

Authors:  F Schumm; H Wiethölter; A Fateh-Moghadam; J Dichgans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-04       Impact factor: 10.154

9.  Microenvironment of thymic myoid cells in myasthenia gravis.

Authors:  T Kirchner; F Hoppe; B Schalke; H K Müller-Hermelink
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1988

10.  Acetylcholine receptor antibodies and anti-idiotypic antibodies produced in blood lymphocyte cultures from patients with myasthenia gravis.

Authors:  A K Lefvert; H Sundén; G Holm
Journal:  Scand J Immunol       Date:  1986-06       Impact factor: 3.487

View more
  6 in total

1.  Ocular myasthenia gravis: response to long-term immunosuppressive treatment.

Authors:  N Sommer; B Sigg; A Melms; M Weller; K Schepelmann; V Herzau; J Dichgans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

2.  Repertoires of autoantibodies against homologous eye muscle in ocular and generalized myasthenia gravis differ.

Authors:  C W Zimmermann; F Eblen
Journal:  Clin Investig       Date:  1993-06

Review 3.  Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.

Authors:  N Sommer; A Melms; M Weller; J Dichgans
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

4.  ["Seronegative" myasthenia with antibodies against muscle-specific tyrosine-kinase].

Authors:  B Hain; F Hanisch; M Deschauer
Journal:  Nervenarzt       Date:  2004-04       Impact factor: 1.214

5.  Autoreactive T Cells from Patients with Myasthenia Gravis Are Characterized by Elevated IL-17, IFN-γ, and GM-CSF and Diminished IL-10 Production.

Authors:  Yonghao Cao; Robert A Amezquita; Steven H Kleinstein; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  J Immunol       Date:  2016-01-29       Impact factor: 5.422

6.  Essential role for autophagy during invariant NKT cell development.

Authors:  Mariolina Salio; Daniel J Puleston; Till S M Mathan; Dawn Shepherd; Amanda J Stranks; Eleni Adamopoulou; Natacha Veerapen; Gurdyal S Besra; Georg A Hollander; Anna Katharina Simon; Vincenzo Cerundolo
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.